Jukka Westermarck and his group received the Elias Tillandz -prize
Prof. Jukka Westermarck and his group received the Elias Tillandz -prize for the best publication of the year for his ground-breaking study on that reveals the druggability of type-2A phosphatase, which has been largely regarded as a non-druggable cancer target. Link to study.
Warmest congratulations to the whole team!
Read more:
Recent Posts
- Doctoral researcher position at Westermarck laboratoryThe Westermarck Laboratory at Turku Bioscience Centre is accepting applications for a doctoral researcher (PhD) Read moreMay 18, 2026
- Early-career researchers invited to BioCity Pre-Symposium on 26 August. Registration is now open!Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026